Protein Biomarkers in Childhood Acute Myeloid Leukemia

儿童急性髓系白血病的蛋白质生物标志物

• 批准号: 8435374
• 负责人: Antonio Bedalov
• 金额: $ 19.49万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-03-01 至 2014-06-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8435374
• 关键词: Acute; Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Acute leukemia; Adult; Allogenic; Aspirate substance; Biological; Biological Assay; Biological Markers; Bone Marrow; Cell physiology; Child; Childhood Acute Myeloid Leukemia; Children' s Oncology Group; Chromosome Mapping; Classification; Clinical; Clinical Data; Clinical Trials; Complement; Cytogenetics; DNA Methylation; DNA amplification; Data; Diagnostic; Disease; Disease remission; Enrollment; Epigenetic Process; Evaluation; Event; Fractionation; Frequencies; Future; Gel; Genes; Genetic; Genetic Markers; Genets; Genomics; Goals; Hematopoietic Neoplasms; Heterogeneity; Individual; Karyotype; Label; Laboratories; Lead; Left; Lesion; Malignant Neoplasms; Marrow; Mass Spectrum Analysis; Measurement; Measures; Messenger RNA; Methods; MicroRNAs; Molecular; Molecular Analysis; Molecular Profiling; Multicenter Trials; Mutation; Myelogenous; Outcome; Outcome Assessment; Pathogenesis; Patients; Pattern; Peptides; Physicians; Preparation; Prognostic Marker; Proteins; Proteome; Proteomics; Protocols documentation; Publishing; Research; Resort; Sampling; Single Nucleotide Polymorphism; Source; Specimen; Stem cell transplant; Technology; Therapeutic; Time; Translating; Transplantation; Yeasts; aggressive therapy; base; chemotherapy; cohort; effective therapy; exome; genome sequencing; high throughput technology; improved; interest; leukemia; mass spectrometer; novel; outcome forecast; prevent; prognostic; prospective; protein expression; response; stable isotope; success; transcriptome sequencing; treatment program; treatment response; tumor

DESCRIPTION (provided by applicant): The goal of our proposal is to identify proteins that serve as prognostic and treatment response biomarkers in childhood acute myeloid leukemia (AML) using specimens from patients enrolled in the Children's Oncology Group (COG) multicenter trials. Our ability to treat cancer more effectively depends critically on improving and refining tumor classifications. This unmet need is particularly acute in childhood AML. As part of the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative, we are analyzing 150 pediatric AML samples with a battery of high throughput technologies in order to identify genomic alterations, epigenetic changes, mRNA and miRNA abundance signatures that may serve as prognostic biomarkers. Because critical aspects of a cell's physiology may be better captured by its protein complement, we propose to carry out proteomic analysis of the same patient cohort using a new method for correlating protein abundance across many samples that was developed in our laboratory. Most currently available proteome profiling technologies (e.g. 2-D gels, ICAT, SILAC) have limitations that prevent their use for profiling large numbers of specimens. We have developed a gel- and isotopic label- free platform for analysis of mass spectrometric data that is capable of profiling large numbers of clinical samples. Our preliminary results demonstrate that our method can identify and quantify a significant portion of the proteome across several hundred samples without resorting to fractionation. Furthermore, we have already demonstrated that this method can differentiate between acute myeloid and acute lymphoid leukemias using protein expression patterns. The proteome analysis of the TARGET cohort in this study will enable us to identify prognostic protein-derived signatures in childhood AML. Multi-analyte signatures will be obtained by integrating protein level measurements with other molecular signatures such as mutational, chromosomal and epigenetic changes obtained by comprehensive sample annotations derived through the TARGET program. Integration of proteomic and genomic signatures will improve our ability to stratify childhood AML sub-types and improve prognostic and therapeutic outcome assessment.

描述（由申请人提供）：我们提案的目标是使用儿童肿瘤学组（COG）多中心试验中招募的患者标本，鉴定作为儿童急性髓性白血病（AML）预后和治疗反应生物标志物的蛋白质。我们更有效地治疗癌症的能力关键取决于改进和完善肿瘤分类。这种未满足的需求在儿童AML中尤为严重。作为产生有效治疗的治疗适用研究（TARGET）计划的一部分，我们正在使用一系列高通量技术分析150例儿童AML样本，以确定可能作为预后生物标志物的基因组改变，表观遗传变化，mRNA和miRNA丰度特征。由于细胞生理学的关键方面可能更好地被其蛋白质补体捕获，我们建议使用一种新方法对同一患者队列进行蛋白质组学分析，该方法用于在我们实验室开发的许多样品中关联蛋白质丰度。 大多数目前可用的蛋白质组分析技术（如2-D凝胶，ICAT，SILAC）有局限性，阻止其用于分析大量的标本。我们已经开发了一种用于分析质谱数据的无凝胶和同位素标记的平台，该平台能够分析大量临床样品。我们的初步结果表明，我们的方法可以识别和定量的蛋白质组的重要组成部分，在几百个样品，而不诉诸分馏。此外，我们已经证明，这种方法可以区分急性髓系和急性淋巴细胞白血病蛋白表达模式。在这项研究中，TARGET队列的蛋白质组分析将使我们能够识别儿童AML中的预后蛋白质来源的特征。将通过整合蛋白质水平测量与其他分子特征（如突变、染色体和表观遗传变化）获得多分析物特征，这些分子特征通过TARGET程序获得的综合样本注释获得。蛋白质组学和基因组特征的整合将提高我们对儿童AML亚型进行分层的能力，并改善预后和治疗结果评估。